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ABSTRACT
Aims: The objective was to evaluate the clinical characteristics, management and two-year out-
comes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in
Nordic countries.
Methods: We examined the baseline characteristics, antithrombotic treatment, and two-year
clinical outcomes of patients from four Nordic countries.
Results: A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European
patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in
combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories:
0–1 (72.8% vs 60.3%), 2–3 (78.7% vs 72.9%) and 4 (79.2% vs 74.1%). In Nordic patients,
NOAC±AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less
often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The
rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embol-
ism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11–4.23) vs 4.08
(3.91–4.26), p value¼ .147] and [0.98 (0.73–1.32) vs 1.02 (0.93–1.11), p value¼ .819], while major
bleeding was significantly higher [1.66 (1.32–2.09) vs 1.01 (0.93–1.10), p value< .001].
Conclusion: Nordic patients had significantly higher major bleeding than Non-Nordic-European
patients. In contrast, rates of all-cause mortality and non-haemorrhagic stroke/SE
were comparable.
Clinical Trial Registration: Unique identifier: NCT01090362. URL: http://www.clinicaltrials.gov.
Key Message: Nordic countries had significantly higher major bleeding than Non-Nordic-
European countries. Rates of mortality and non-haemorrhagic stroke/SE were similar .
ARTICLE HISTORY
Received 14 October 2020
Revised 9 February 2021






One in four individuals is expected to develop atrial
fibrillation (AF) after the age of 40 [1–3], and the
prevalence and incidence of patients with this condi-
tion are predicted to rise considerably in the next few
decades. The exact reasons are unknown, but it has
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been partly explained by an increase in comorbidities
and cardiovascular risk factors, and an ageing popula-
tion [4–6]. AF is related to higher risk of mortality and
morbidity, the risk of stroke being nearly fivefold
increased [7–11] and the severity of these cardio-
embolic strokes tends to be greater than atheroscler-
otic strokes [12,13]. Oral anticoagulation (OAC) can
prevent major ischaemic events and prolong patient
lives and is, therefore, an integral part of the clinical
management of AF patients [1,12].
Non-vitamin K antagonist oral anticoagulants (NOACs)
have been shown to reduce the rate of all-cause mortal-
ity, stroke/systemic embolism (SE) and intracranial haem-
orrhage when compared to vitamin K-antagonists (VKA)
in patients with non-valvular AF, with a faster onset of
action, fewer interactions and no requirement for INR-
monitoring [14–17]. Treatment with antiplatelet drugs
(AP) has been shown to be substantially less effective
than OAC while bleeding risk is similar [18,19].
Consequently, for stroke prevention in the non-valvular
AF patient population, European, American, Canadian
and Asia-Pacific guidelines consider NOACs the first
choice in antithrombotic treatment, while AP therapy is
not recommended [1,20,21].
The Global Anticoagulant Registry in the FIELD-AF
(GARFIELD-AF) is a prospective, international, multi-
centre registry of adult patients with newly diagnosed
non-valvular atrial fibrillation (NVAF) and one or more
additional risk factors for stroke. The main goal of the
registry is to identify best practices as well as differen-
ces in stroke prevention strategies for AF patients.
There might be substantial regional and intraregional
differences among baseline characteristics and use of
antithrombotic therapies in patients with new NVAF
[22,23]. To our knowledge, no studies have investi-
gated the combined Nordic AF patient population
apart from a few individual national studies [8,13,24].
All the Nordic countries are followers of the welfare
state concept with similar healthcare systems and
some individual differences [25]. Therefore, we aimed
to assess the baseline characteristics, antithrombotic
treatment and clinical outcomes through 24months
for patients in Nordic countries, and the results were
compared with patients from Non-Nordic European
countries. For clinical outcomes, results were also com-
pared with Non-European countries.
Methods
Study design and participants
The Global Anticoagulant Registry in the FIELD in AF
(GARFIELD-AF) is an international registry of adult
patients with newly diagnosed non-valvular (AF) with
at least one additional risk factor for stroke [22,23].
Patients were enrolled prospectively and consecutively
in 35 countries and 5 consecutive cohorts of approxi-
mately 10,000 patients with intended 2-year follow-up.
A total of 52,080 patients were prospectively enrolled
(2010–2016) from 35 countries and 29,908 patients
were registered from Europe, and of these 2,396 from
the four Nordic countries (Sweden, Denmark, Finland
and Norway). The sites were randomly selected and
when random site selection did not generate the
required number of sites in a given country, the
national lead investigators were asked to recommend
sites to make up the numbers (18 out 1317 sites). The
sites represent different care settings in each partici-
pating country (office-based practice; hospital depart-
ments including neurology, cardiology, geriatrics,
internal medicine, and emergency; anticoagulation
clinics; and general or family practice)
Data collection
Data collection at baseline included patient demo-
graphics, medical history, care setting, type of AF (also
collected during follow-up), and antithrombotic treat-
ment (vitamin K antagonists, non-vitamin K antagonist
oral anticoagulants, and antiplatelet treatment). Data
on components of the CHA2DS2-VASc and HAS-BLED
risk stratification schemes were used to assess the
risks of stroke and bleeding, retrospectively. HAS-BLED
scores were calculated excluding fluctuations in the
international normalized ratio. In addition, the risks of
death, stroke/SE and major bleeding were assessed at
baseline with the recently described GARFIELD-AF risk
calculator [26].
Patients were contacted at 4-monthly intervals via
telephone or postal mail. Data were collected using an
electronic case report form and were examined for
completeness and accuracy by the coordinating centre
(Thrombosis Research Institute, London, UK). In
accordance with the study protocol, 20% of all data
submitted electronically were monitored against
source documentation [27].
Initiated antithrombotic treatments were catego-
rized as VKA, NOACs [Factor Xa inhibitors (FXaI) and
Direct Thrombin inhibitors (DTI)], and AP, alone or in
combination. The incidences of stroke/systemic embol-
ism, major bleeding, all-cause death, cardiovascular
and non-cardiovascular death, acute coronary syn-
dromes, and congestive heart failure were recorded
over two years. Only the first occurrence of an event
was considered. Data used in this analysis were
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extracted from the GARFIELD-AF registry in
November 2018.
Clinical events were defined using standardized def-
initions, which have been reported previously [22,23] .
Vascular disease included peripheral artery disease
and/or coronary artery disease. Chronic kidney disease
was classified according to National Kidney
Foundation guidelines into two groups; moderate-to-
severe (stages 3–5), or mild (stages 1 and 2) or none
[28]. Congestive heart failure was defined as current/
prior history of congestive heart failure or left ven-
tricular ejection fraction of <40%.
Ethics statement
All patients signed written informed consent to partici-
pate prior to enrolment. Approvals for the registry
protocol were obtained from independent ethics com-
mittees and/or hospital-based institutional boards. The
database is being conducted according to the princi-
ples of the Declaration of Helsinki and the International
Conference on Harmonisation – Good Pharmaco-epi-
demiological and Clinical Practice guidelines.
Statistical analyses
Categorical variables were expressed as percentages
and frequency, and continuous variables as mean-
± standard deviation (SD). Clinical outcomes were pre-
sented as person-time event rates (per 100 person-
years) with 95% confidence intervals. Differences in
baseline characteristics were performed using chi-
square tests for categorical variables and Wilcoxon
sign-rank tests for continuous variables. Statistical
analyses were performed using SASVR software version
9.4 (SAS Institute Inc., Cary, NC, USA.)
Results
A total of 2,396 patients from four Nordic countries,
Sweden (n¼ 1,233), Denmark (n¼ 532), Finland
(n¼ 359) and Norway (n¼ 272), were included in the
study. From Non-Nordic-European countries, 27,512
patients were enrolled from Austria, Belgium, The
Czech Republic, France, Germany, Hungary, Italy, the
Netherlands, Poland, Russia, Spain, Switzerland, Turkey,
Ukraine and the United Kingdom (Figure 1).
Figure 1. Nordic and Non-Nordic European countries with number of patients included.
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Care setting
In Nordic countries, care-setting speciality at diagnosis
was cardiology (45.4%), primary care/general practice
(27.9%), followed by internal medicine (23.3%). In
Non-Nordic-European countries, speciality at diagnosis
was cardiology (57.3%), internal medicine (20.9%) fol-
lowed by general practitioners (19.3%) (Table 1).
Patient characteristics
Nordic countries patients were older (mean age
71.7 years) than those in Non-Nordic European coun-
tries (mean age 70.6 years), and a larger group were
65 years (Nordic 80.1%, Non-Nordic European 72.6%)
(Table 2).
The number of patients with a history of hyperten-
sion, hypercholesterolaemia and vascular disease was
lower in the Nordic patients than in the Non-Nordic
European patients (69.4% vs 80.5%, 36.1% vs 47.2%,
15.9% vs 28.7% respectively). Congestive heart failure
(CHF) and moderate to severe chronic kidney disease
(CKD) were also less common in Nordic patients
(14.5% vs 23.6%) and (7.9% vs 12.8%).
The mean CHA2DS2 and CHA2DS2-VASc scores in
Nordic countries were 1.8 and 3.2, and in Non-Nordic
European patients 1.9 and 3.4, respectively. Almost 9
out of 10 patients in Nordic and Non-Nordic European
Table 1. Care-setting speciality at diagnosis in Nordic and Non-Nordic European countries, and in the four Nordic countries














Internal Medicine, n (%) 559 (23.3) 5754 (20.9) 296 (24.0) 38 (7.1) 189 (52.6) 36 (13.2)
Cardiology, n (%) 1089 (45.4) 15,757 (57.3) 485 (39.3) 410 (77.1) 33 (9.2) 161 (59.2)
Neurology, n (%) 73 (3.0) 550 (2.0) 15 (1.2) 6 (1.1) 51 (14.2) 1 (0.4)
Geriatrics, n (%) 6 (0.3) 142 (0.5) 2 (0.2) 4 (0.8) 0 (0.0) 0 (0.0)
Primary Care/General Practice, n (%) 669 (27.9) 5306 (19.3) 435 (35.3) 74 (13.9) 86 (24.0) 74 (27.2)





(n¼ 27,512) p Value
Male, n (%) 1389 (58.0) 14,944 (54.3) <.001
Age at diagnosis, mean (SD) 71.7 (9.7) 70.6 (11.1) <.001
Age group, n (%) <.001
<65 476 (19.9) 7549 (27.4)
65–69 413 (17.2) 4171 (15.2)
70–74 491 (20.5) 4693 (17.1)
75 1016 (42.4) 11,099 (40.3)
BMI (kg/m2), mean (SD) 28.2 (5.8) 28.9 (5.5) <.001
Pulse (bpm), mean (SD) 100.2 (30.7) 90.3 (26.8) <.001
Systolic BP (mmHg), mean (SD) 139.1 (21.4) 135.6 (19.2) <.001
Hypertension, n (%) 1659 (69.4) 22,104 (80.5) <.001
Hypercholesterolaemia, n (%) 845 (36.1) 12540 (47.2) <.001
Diabetes, n (%) 387 (16.2) 5981 (21.7) <.001
Heart failure, n (%) 348 (14.5) 6497 (23.6) <.001
Vascular diseasea, n (%) 379 (15.9) 7845 (28.7) <.001
History of stroke/TIA/SE, n (%) 323 (13.5) 3125 (11.4) .002
History of bleeding, n(%) 46 (1.9) 719 (2.6) .039
Moderate to Severe CKD, n(%) 185 (7.9) 3424 (12.8) <.001
Type of AF, n (%) <.001
Permanent 222 (9.3) 4367 (15.9)
Persistent 160 (6.7) 4160 (15.1)
Paroxysmal 529 (22.1) 6853 (24.9)
Unclassified 1485 (62.0) 12,129 (44.1)
Alcohol consumption light to heavy, n (%) 1095 (80.3) 11,883 (50.3) <.001
Ex-/Current smoker, n (%) 707 (40.1) 8861 (34.8) <.001
CHADS2 Score, mean (SD) 1.8 (1.1) 1.9 (1.1) <.001
CHA2DS2-VASc Score, mean (SD) 3.2 (1.5) 3.4 (1.6) <.001
CHA2DS2-VASc score 2, n (%) 2086 (87.6) 23,960 (88.2) .408
HAS-BLED score, mean (SD) 1.4 (0.9) 1.4 (0.9) .002
GARFIELD-AF Score for deathb, mean (SD) 6.6 (6.5) 7.7 (5.4) <.001
GARFIELD-AF Score for strokeb, mean (SD) 1.9 (1.4) 2.0 (1.5) .002
GARFIELD-AF Score for major bleedingd, mean (SD) 2.0 (1.3) 2.1 (1.5) .050
aDefined as peripheral vascular disease and/or coronary artery disease.
bIndicates the probability of death occurrence within 2 years of follow-up.
cIndicates the probability of non-haemorrhagic stroke occurrence within 2 years of follow-up.
dIndicates the probability of major bleeding occurrence within 2 years of follow-up.
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patients had a CHA2DS2-VASc  2 (87.6% and 88.2%).
The mean HAS-BLED score was 1.4 for both Nordic
and Non-Nordic-European patients. The GARFIELD-AF
score showed that Nordic patients had a lower
expected rate of all-cause mortality and stroke, while
the expected rate of bleeding was comparable to
Non-Nordic Europeans.
A high frequency of smoking was observed in both
Nordic and Non-Nordic European patients (40.1% and
34.8%, respectively). The proportion of patients drink-
ing alcohol (light to heavy consumption), was higher
in Nordic patients (80.3%) than Non-Nordic European
patients (50.3%).
Clinical characteristics for patients from the four
Nordic countries are shown in Table 3.
Antithrombotic therapy
Figure 2 depicts the distribution of antithrombotic
therapies. Over 90% of the European patients (Nordic
and Non-Nordic) received antithrombotic therapy. A
total of 11.4% and 9.8% of patients respectively in
Nordic and Non-Nordic European countries did not
receive any antithrombotic therapy. Nordic countries
had a higher use of OAC, alone or in combination
with AP, in all CHA2DS2-VASc categories; 0–1 (72.8% vs
60.3%), 2–3 (78.7% vs 72.9%) and 4 (79.2% vs
74.1%), and lower use of AP monotherapy than Non-
Nordic European countries in all CHA2DS2-VASc cate-
gories; 0–1 (7.6% vs 19.8%), 2–3 (8.8% vs 17.0%), 4
(13.4% vs 19.0%). In both Nordic and Non-Nordic
European patient populations, more than four in five











Age at Diagnosis, mean (SD) 72.9 (8.7) 71.5 (10.8) 69.8 (10.3) 69.6 (10.0)
BMI (kg/m2), mean (SD) 27.9 (5.4) 27.9 (5.6) 30.5 (7.4) 28.5 (5.8)
Systolic BP (mmHg), mean (SD) 138.1 (19.4) 138.4 (21.4) 143.7 (26.5) 137.8 (20.6)
Hypercholesterolaemia, n (%) 341 (28.6) 233 (44.7) 137 (38.4) 134 (49.4)
Diabetes, n (%) 199 (16.1) 74 (13.9) 80 (22.3) 34 (12.5)
Stroke/TIA/SE, n (%) 147 (11.9) 64 (12.1) 88 (24.5) 24 (8.9)
Heart failure, n (%) 136 (11.0) 113 (21.2) 69 (19.2) 30 (11.0)
CHA2DS2-VASc Score, mean (SD) 3.1 (1.4) 3.2 (1.5) 3.5 (1.6) 2.8 (1.4)
Figure 2. Antithrombotic treatment in CHA2DS2-VASc categories 0–1, 2–3, 4 in Nordic and Non-Nordic European countries. AP:
antiplatelet; DTI: direct thrombin inhibitors; FXaI: factor Xa inhibitors; VKA: vitamin K antagonists.
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patients in CHA2DS2-VASc category 0–1 received
antithrombotic treatment (80.4% vs 80.1%). The per-
centage of patients on antithrombotic therapy
increased with higher CHA2DS2-VASc score (Figure 2).
For patients treated with VKA, the mean INR value
was 2.41 (SD: 0.80) in Nordic and 2.46 (SD: 0.87) in
Non-Nordic-European countries. The percentage of
patients with a mean Time in Therapeutic Range [29]
 65 was 65.1% in Nordic patients and 47.7% for
Non-Nordic-European patients.
Patients from Finland differed from those from
other Nordic countries by more frequently receiving
VKA±AP (69%), and less frequently NOACs ±AP
(6.2%). Finland was also the Nordic country with the
highest use of AP monotherapy (13.4%), while Norway
was the country with the lowest prescription of AP
monotherapy (5.2%). Norway had the highest use of
OAC treatment (86.6%); the overall proportion for
Nordic countries was 78.3%.
Event rate
Figure 3 shows the clinical event rates per 100 per-
son-years to 2 years of follow-up (95% confidence
intervals), stratified according to the populations
studied. In this section, we also included data from
the Non-European countries in the GARFIELD-AF data-
base for comparison. The incidence of non-haemor-
rhagic stroke/systemic embolism (SE) was lower [0.98
(0.73–1.32) vs 1.02 (0.93–1.11), p value .819] and major
bleeding was significantly higher [1.66 (1.32–2.09) vs
1.01 (0.93–1.10), p value <.001] in the Nordic patient
population compared to the Non-Nordic-European
patient population (Table 4). New or worsening CHF
was significantly higher in the Nordic patients [1.70
(1.36–2.14) vs 1.01 (0.92–1.10), p value <.001]. For
Non-European patients the event rate per 100 person-
years were 0.97 (0.88–1.07) for non-haemorrhagic
stroke/SE, 0.85 (0.76–0.94) for major bleeding and 0.66
(0.58–0.74) for new or worsening CHF.
Figure 4 depicts the mortality event rates per 100
person-years. Patients in Nordic countries had numeric-
ally lower event rates than patients in Non-Nordic
European countries of all-cause mortality [3.63
(3.11–4.23) vs 4.08 (3.91–4.26), p value 0.147], cardiovas-
cular mortality [1.17 (0.90–1.54) vs 1.52 (1.41–1.63), p
value .070] and non-cardiovascular mortality [1.50
(1.19–1.91) vs 1.58 (1.48–1.70), p value .681] (Table 4). For
Non-European patients the rates were 3.52 (3.34–3.70),
1.18 (1.08–1.29) and 1.30 (1.19–1.41), respectively.
Figure 3. Clinical event rate (event per 100 person-years) through 2-year follow-up in Nordic, Non-Nordic European and Non-
European countries.
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Within the Nordic countries, the rates of all-cause
mortality were relatively high in Denmark [6.37
(4.97–8.17)], and low in Norway [1.89 (1.01–3.51)]. For
Finland and Sweden, the rates were 2.47 (1.54–3.98)
and 3.22 (2.57–4.04). In Finland and Denmark, the
occurrence of new or worsening CHF was higher, 5.22
(3.71–7.35) and 2.89 (1.98–4.21) respectively. The event
rate of non-haemorrhagic stroke/SE was 0.65
(0.39–1.07) in Sweden, 1.17 (0.59–2.34) in Finland, 1.34
(0.64–2.80) in Norway and 1.46 (0.87–2.47) in
Denmark, and for major bleed, it was 1.17 (0.80–1.71)
in Sweden, 1.93 (1.12–3.32) in Finland, 1.93 (1.04–3.58)
in Norway and 2.51 (1.69–3.75) in Denmark.
Discussion
Prior to the present study, several articles from differ-
ent Nordic countries have been published [8,13,24],
while data on the Nordic patient population as a
whole, with information on risk factors, treatment
practices and clinical outcomes, has not been pub-
lished to our knowledge.
Table 4. Clinical outcomes through 2-year follow-up in Nordic, Non-Nordic European and Non-European countries.
Outcome
Nordic Non-Nordic European Non-European
Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI)
Non-haemorrhagic stroke/SE 44 0.98 (0.73–1.32) 520 1.02 (0.93–1.11) 393 0.97 (0.88–1.07)
Major bleeding 74 1.66 (1.32–2.09) 517 1.01 (0.93–1.10) 344 0.85 (0.76–0.94)
Acute coronary syndrome 28 0.62 (0.43–0.90) 372 0.73 (0.66–0.81) 202 0.50 (0.43–0.57)
New or worsening HF 75 1.70 (1.36–2.14) 511 1.01 (0.92–1.10) 265 0.66 (0.58–0.74)
Primary ischaemic stroke 32 0.71 (0.50–1.01) 369 0.72 (0.65–0.80) 284 0.70 (0.62–0.79)
Primary haemorrhagic stroke 7 0.16 (0.07–0.33) 61 0.12 (0.09–0.15) 46 0.11 (0.08–0.15)
All-cause mortality 164 3.63 (3.11–4.23) 2102 4.08 (3.91–4.26) 1436 3.52 (3.34–3.70)
Cardiovascular mortality 53 1.17 (0.90–1.54) 781 1.52 (1.41–1.63) 480 1.18 (1.08–1.29)
Non-cardiovascular mortality 68 1.50 (1.19–1.91) 816 1.58 (1.48–1.70) 530 1.30 (1.19–1.41)
Figure 4. Mortality event rate (event per 100 person-years) through 2-year follow-up in Nordic, Non-Nordic European and Non-
European countries.
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Intra-Nordic differences
The data from the Nordic countries: Sweden (n¼ 1
233), Denmark (n¼ 532), Finland (n¼ 359) and Norway
(n¼ 272) showed some interesting observations.
Patients from Finland had higher comorbidity at base-
line, with more diabetes, history of stroke/TIA and
CHF. In addition, Finland had a more frequent use of
VKA than the other Nordic countries, which might be
due to lack of reimbursement to NOACs prescriptions.
All-cause mortality rate was considerably higher in
Denmark than in the other Nordic countries. Even
though these findings might reflect actual dissimilar-
ities between the countries, these might be due to
the different care settings in which the patients were
diagnosed. For instance, a higher percentage of
patients from Denmark were recruited by cardiologists
and patients from Finland by internists than their
counterparts in Sweden and Norway, which might
explain their increased morbidity and mortality.
Nordic versus Non-Nordic European comparisons
Based on our findings, Nordic patients were older
than Non-Nordic European patients, but the latter had
a higher risk profile and morbidity at baseline.
Nine in ten European patients received antithrom-
botic treatment, and almost the same percentage of
patients had a CHA2DS2-VASc score 2, with an esti-
mated annual adjusted stroke rate ranging from 2.2%
to 15.2% [30]. Stroke prevention therapy, therefore,
seems to be extensively employed. At the same time,
the use of AP monotherapy is quite high in Non-
Nordic European countries, where it was prescribed to
almost one in five patients. In contrast, the Nordic
countries, only one in ten patients received the AP
monotherapy. There may be many reasonable factors
influencing the therapeutic choices, but this might
also reflect a potential for improvement on the choice
of antithrombotic drug for stroke prevention in AF,
especially in Non-Nordic European countries. One pos-
sible explanation for the difference in treatment might
be the cost for the individual patient for doctor
appointments (e.g. INR controls when treatment with
warfarin) and for the medicine, as acetylsalicylic acid is
far cheaper than AC treatment. In Nordic countries the
healthcare is tax financed with universal coverage and
minimal direct patient cost, and prescription medicine
is financed by the government [31].
In Nordic and Non-Nordic European patients with a
CHA2DS2-VASc score of 0–1, regarded to be at very
low risk of stroke [32], more than four in five patients
received antithrombotic therapy. Over 70% of Nordic
and almost 60% of Non-Nordic European patients in
this CHA2DS2-VASc category received OAC. Although
this may represent overtreatment, one of the inclusion
criteria for patients in this study was AF with at least
one additional risk factor for stroke. This additional
risk factor might have been modified and thus not
have been present over time, and could conceivably
be the reason why so many patients received OAC. In
the future, GARFIELD-AF score might help to identify
the patients who are at low risk of stroke who would
reasonably not need to receive AC therapy.
Nordic versus Non-Nordic european versus global
comparisons
For the particular analysis of clinical endpoints, our
analysis encompassed a global (non-European) com-
parison cohort, in addition to the Nordic and non-
Nordic European cohorts. The event rate of stroke was
lower in Nordic and Non-European countries com-
pared to Non-Nordic European countries. This could
partly be explained by the difference in baseline risk
of stroke, as Nordic patients had lower proportion of
patients with CKD, vascular disease, CHF and diabetes
than Non-Nordic European patients, which are all
known risk factors for stroke [33]. Another contributing
factor could be that Nordic patients received more
guideline-recommended antithrombotic treatment.
The event rate of major bleeding was higher in Nordic
patients than Non-Nordic European and Non-European
patients. Nordic patients were older, a higher percentage
had a history of stroke at baseline and the proportion of
the population consuming alcohol was higher than in the
Non-Nordic European population. They also had less CKD
and vascular disease, other known risk factors for bleed-
ing [33]. Despite a lower risk profile for bleeding in
Nordic versus Non-Nordic European patients, there was
an increased event rate of major bleeding, which could
partly be caused by a higher percentage of Nordic
patients receiving OAC treatment. In particular, a higher
proportion of VKA±AP prescription among patients with
CHA2DS2-VASc 4 in Nordic vs non-Nordic was observed;
50.6% vs 46.6% respectively. The difference in major
bleeding rates was mostly evident in this high-risk group
[2.91 (2.19–3.86) in Nordic patients vs 1.36 (1.22-1.52) in
Non-Nordic European patients].
All-cause mortality and cardiovascular mortality
were lower in Nordic and non-European countries
than in Non-Nordic European countries, which might
be explained by a combination of lower comorbidity
and baseline risk for death, and different antithrom-
botic treatment.
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Limitations
The GARFIELD-AF is an observational study and the
data collection is non-randomized. As with all registry
data, this must be taken into careful consideration
when interpreting these data. Countries varied in care
settings where patients were enrolled, which may
have influenced patient characteristics, disease sever-
ity, as well as treatment decisions. Further, the registry
was limited to patients with newly diagnosed AF.
Results can therefore not a priori be extrapolated to a
general cohort of chronic AF.
Conclusion
The use of antithrombotic treatment in patients with
AF in Europe is high. There is a need for management
of patients according to the guidelines, especially in
Non-Nordic-European countries. Nordic countries had
significantly higher major bleeding than Non-Nordic-
European countries. In contrast, rates of mortality and
non-haemorrhagic stroke/SE were similar with a non-
significant lower trend.
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